Abstract | OBJECTIVES: Assessment of surgical outcome in acromegaly is typically recommended at 3 to 6 months following surgery. The purpose of this study was to determine if insulin-like growth factor 1 (IGF-1) concentrations at 6 weeks were equally predictive of surgical outcomes compared with IGF-1 concentrations at 3 to 6 months postoperatively applying newer IGF-1 assays. METHODS: Retrospective review of patients with newly diagnosed acromegaly who had surgery between 2013 and 2020 and had postoperative IGF-1 measured by 6 weeks and 3 to 6 months. RESULTS: At 6 weeks, 20 (35%) of the total 57 had normal IGF-1 and became abnormal in 1 at 3 to 6 months, whereas 37 (65%) of 57 had abnormal IGF-1 concentrations at 6 weeks, which normalized in 1 patient by 3 to 6 months. In patients who changed clinical status, IGF-1 at 6 weeks was within ±0.1-fold of normal. Although a difference was seen between median IGF-1 concentrations (286 vs 267 ng/mL, P = .009) at 6 weeks and 3 to 6 months, the mean reduction was small (-19.9 ng/mL). CONCLUSIONS: Compared with 3 to 6 months, use of IGF-1 at 6 weeks was associated with a change in clinical status in 3.5% of patients. Therefore, in most patients, IGF-1 at 6 weeks can be used to assess clinical outcome via newer assays.
|
Authors | Diane Donegan, Alicia Algeciras-Schimnich, Susan Ashrafzadeh-Kian, Dana Erickson |
Journal | American journal of clinical pathology
(Am J Clin Pathol)
Vol. 157
Issue 4
Pg. 595-601
(04 01 2022)
ISSN: 1943-7722 [Electronic] England |
PMID | 34665848
(Publication Type: Journal Article)
|
Copyright | © American Society for Clinical Pathology, 2021. All rights reserved. For permissions, please e-mail: [email protected]. |
Chemical References |
- IGF1 protein, human
- Insulin-Like Growth Factor I
|
Topics |
- Acromegaly
(diagnosis, metabolism, surgery)
- Humans
- Insulin-Like Growth Factor I
(metabolism)
- Postoperative Period
- Retrospective Studies
|